Financial Data and Key Metrics Changes - Hua Medicine achieved a revenue growth of 93% in 2025, with sales reaching close to CNY 500 million, driven by a 91% increase in packs sold compared to 2024 [3][19] - The gross profit margin is expected to rise to 70%-75% over the next couple of years, reflecting economies of scale and reduced distribution costs [20][47] - The company reported a significant reduction in selling expenses as a percentage of sales, dropping from nearly 60% in 2024 to 33% in 2025 [21][23] Business Line Data and Key Metrics Changes - The establishment of over 180 professional sales teams has enabled Hua Medicine to cover over 3,000 hospitals and reach over 150,000 patients in mainland China [4][5] - The commercialization strategy has shifted from relying on partners to an in-house team, which has significantly improved market access and sales performance [4][19] Market Data and Key Metrics Changes - The company has extended its glucokinase activator program into the glucose homeostasis technology platform, targeting the 100 million diabetes patients in Southeast Asia [3][16] - The market exclusivity for dorzagliatin has been extended to 2034, supported by government policies that maintain the same reimbursement price for 2026 and 2027 [5][39] Company Strategy and Development Direction - Hua Medicine is focusing on expanding its market access and commercialization capabilities, particularly in the Greater Bay Area, to push dorzagliatin into Southeast Asia [16][18] - The company is also exploring new indications for dorzagliatin, including obesity, NASH, and early Alzheimer's disease, leveraging its glucose homeostasis technology platform [18][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sales targets of CNY 1 billion by 2027, citing strong patent protection, stable pricing, and effective promotion strategies as key factors [31][34] - The management highlighted the importance of real-world evidence and investigator-initiated trials in demonstrating the drug's efficacy and safety, which are expected to drive future growth [22][43] Other Important Information - Hua Medicine has received IND approval for a fixed-dose combination of dorzagliatin with metformin, with an NDA filing expected in 2027 [18][27] - The company is actively seeking partnerships for its second-generation products and exploring in-licensing opportunities to enhance its pipeline [28][58] Q&A Session Summary Question: What are the sales targets for the next two years? - Management remains confident in achieving CNY 1 billion in sales by 2027, supported by patent protection and stable pricing strategies [31][34] Question: What is the progress on the pipeline for the second generation of GKA? - Management indicated that promising data from ongoing studies will guide interactions with regulatory agencies for product launch [32][37] Question: What are the expectations for operating expenses in the coming years? - Selling expenses are expected to stabilize around 30-35%, while R&D expenses will be maintained at approximately 30% to support ongoing projects [44][51]

Dorzagliatin Overview - Dorzagliatin is a first-in-class drug with global rights, targeting the underlying cause of Type 2 Diabetes (T2D) by addressing impaired glucose homeostasis[13] - As of December 31, 2019, Hua Medicine had RMB 1.1 billion in cash[13] - The global T2D population is 453 million, with 120 million in China alone, representing a massive market opportunity[13] Clinical Trial Results - In a Phase III monotherapy trial, dorzagliatin achieved the primary endpoint, demonstrating a significant and sustainable reduction in HbA1c safely[13] - In the HMM0301 Phase III trial, the dorzagliatin-treated group showed a 1.07% HbA1c reduction from a baseline of 8.35%, compared to a 0.5% reduction from a baseline of 8.37% in the placebo group (p < 0.0001)[62] - 45.4% of patients treated with dorzagliatin achieved a target HbA1c level of 7.0% or less at 24 weeks, compared to 21.5% of patients treated with placebo (p < 0.0001)[62] - Patients treated with dorzagliatin achieved a homeostasis control rate of 45.0% compared with 21.5% in the placebo group (p < 0.0001)[62] Combination Therapy - A Phase I trial (HMM0111) showed that dorzagliatin combined with sitagliptin (DPP-4 inhibitor) resulted in a 33% reduction (p<0.01) in postprandial glucose level AUEC (0-4hr)[74] - A Phase I trial (HMM0112) showed that dorzagliatin combined with empagliflozin (SGLT-2 inhibitor) resulted in a 38% reduction (p<0.0001) in postprandial glucose level AUEC (0-4hr)[79] China Market - China has the largest diabetes population globally, with approximately 125 million T2D patients[232] - The diagnosis rate in China was 50.4% in 2018 and is expected to rise to 82.2% in 2028[235] - The China anti-diabetics market is projected to grow from RMB 57.3 billion in 2018 to RMB 135.6 billion in 2025, with an expected CAGR of 11.7% from 2018 to 2028[246]